Introduction {#j_bjmg-2016-0010_s_001}
============

Clinical anophthalmia is a rare genetic disease of the eye and phenotype refers to the absence of ocular tissue in the orbit of eye \[[@j_bjmg-2016-0010_ref_001]-[@j_bjmg-2016-0010_ref_003]\]. Congenital clinical anophthalmia is commonly bilateral \[[@j_bjmg-2016-0010_ref_004]\] but it may also be unilateral \[[@j_bjmg-2016-0010_ref_005]\]. Often anophthalmia is part of a syndrome and is accompanied by other brain anomalies \[[@j_bjmg-2016-0010_ref_006],[@j_bjmg-2016-0010_ref_007]\]. Clinically, in the absence of apparent ocular tissue, congenital anophthalmia and extreme microphthalmia (A/M), *i.e*., the presence of a small eye, are considered the same, because computerized tomography (CT) scan investigations indicated residual neuroectoderm in the orbit of the eye in some cases \[[@j_bjmg-2016-0010_ref_008]\].

Clinical anophthalmia exhibits different patterns of genetic inheritance, *i.e*. autosomal dominant, autosomal recessive and X-linked recessive \[[@j_bjmg-2016-0010_ref_004],[@j_bjmg-2016-0010_ref_009]\]. Studies on autosomal recessive mode of inheritance of anophthalmia have rarely been reported \[[@j_bjmg-2016-0010_ref_001],[@j_bjmg-2016-0010_ref_010]\]. Similarly, previous research studies have also provided rare evidence about consanguinity association with congenital anophthalmia \[[@j_bjmg-2016-0010_ref_008],[@j_bjmg-2016-0010_ref_011]\].

Anophthalmia/microphthalmia cause a considerable percentage of congenital visual impairments in children \[[@j_bjmg-2016-0010_ref_012]\]. Epidemiological data has reported that the prevalence of congenital anophthalmia is three in 100,000. However, other evidence estimated the combined prevalence of congenital anophthalmia and microphthalmia up to three in 100,000 \[[@j_bjmg-2016-0010_ref_013],[@j_bjmg-2016-0010_ref_014]\]. In developed countries, a prevalence of 0.2-0.4 per 10,000 births has been reported \[[@j_bjmg-2016-0010_ref_015]-[@j_bjmg-2016-0010_ref_017]\]. Epidemiological studies have also investigated some risk factors for anophthalmia including late maternal age, multiple births \[[@j_bjmg-2016-0010_ref_015],[@j_bjmg-2016-0010_ref_016]\], low birth weight and premature birth complications \[[@j_bjmg-2016-0010_ref_018]\]. Epidemiological studies have reported that both genetic and environmental factors cause anophthalmia and microphthalmia, however, environmental factors account for a lesser number of cases \[[@j_bjmg-2016-0010_ref_004]\].

Genetic linkage analysis studies have identified the same loci and mutations in the same genes for both clinical anophthalmia and extreme microphthalmia \[[@j_bjmg-2016-0010_ref_004]\]. It was considered that congenital A/M showed genetic heterogeneity due to linkage of a large number of loci with them. Similarly, mutations in several well-defined human genes such as *CHX10, RAX, SOX2* and *OTX2*, are also associated with heritable forms of clinical anophthalmia and severe microphthalmia \[[@j_bjmg-2016-0010_ref_009]\].

In the Khyber Pakhtunkhwa region of Pakistan, different Pashtoon tribes are prominent ethnic groups and due to cultural impacts, they have very strong reservations regarding marriages outside their tribal boundaries, as they believe that dilution of tribal blood may result in losing their specific tribal characteristics. Moreover, they practice consanguineous marriages to strengthen family ties and to maintain the family structure and property \[[@j_bjmg-2016-0010_ref_019]\]. The causes of congenital inherited diseases in Khyber Pakhtunkhwa are maternal illiteracy, mother's age to be less than 20 years at the birth of first child, birth interval of less than 18 months \[[@j_bjmg-2016-0010_ref_020]\], and the influencing culture factor to have more children, particularly sons, until menopause. The lack of public awareness toward prenatal diagnosis or prevention of inherited disease and health risks associated with consanguineous unions, is limited. Many people do not agree with medical explanations of a genetic mode of disease inheritance, even in case where there is an affected child. Because of this, inherited diseases are frequently observed in Khyber Pakhtunkhwa that follow Mendelian patterns of inheritance, and the molecular bases are not known. In present study, a consanguineous Pakistani family of the Pashtoon ethnic group with isolated clinical anophthalmia in Khyber Pakhtunkhwa was investigated.

Materials and Methods {#j_bjmg-2016-0010_s_002}
=====================

Ascertainment of Family {#j_bjmg-2016-0010_s_002_s_001}
-----------------------

This study was approved by the Ethics Committee of the Department of Biotechnology and Genetic Engineering, Kohat University of Science and Technology, Khyber Pakhtunkhwa, Pakistan. A consanguineous Pakistani family of the Pashtoon ethnic group with bilateral clinical anophthalmia, in which disease was segregating as an autosomal recessive trait, was ascertained. This family resided in the southern region of Khyber Paktunkhwa, Pakistan, known as Kohat, which is inhabited by various Pashtoon tribes ([Figure 1](#j_bjmg-2016-0010_fig_001){ref-type="fig"}). It was observed that ocular tissue was absent in the orbit of the eyes in affected offspring ([Figure 2](#j_bjmg-2016-0010_fig_002){ref-type="fig"}). On the basis of clinical features assessed by slit lamp examination and radiological assessment by CT scanning, the ophthalmologist diagnosed the anophthalmia as an isolated entity and having no syndromic presentation in the affected daughters. Written informed consent was obtained from the elders of this family to participate in the study. A pedigree of the family was created from information provided by the family using the Cyrillic (version 2.10) program (<http://www.cherwell.com>).

![Map of Pakistan showing the provincial subdivisons; detailed map of Khyber Pakhtunkhwa with the Kohat region highlighted.](j_bjmg-2016-0010_fig_001){#j_bjmg-2016-0010_fig_001}

![Photograph of the eye of an anophthalmic patient of a Pakistani family.](j_bjmg-2016-0010_fig_002){#j_bjmg-2016-0010_fig_002}

Blood Sample Collection and DNA Extraction {#j_bjmg-2016-0010_s_002_s_002}
------------------------------------------

Blood samples were collected in 10 mL vacutainer tubes (Becton Dickinson, Mountain View, CA, USA) with written informed consent from six individuals including four clinically normal (2MOP001, 2MOP002, 2MOP004, and 2MOP005), and two affected (2MOP003, and 2MOP006) daughters of this family. Genomic DNA was extracted from peripheral blood samples following the standard phenolchloroform extraction procedure \[[@j_bjmg-2016-0010_ref_021]\].

Genotyping and Linkage Analysis {#j_bjmg-2016-0010_s_002_s_003}
-------------------------------

Identification of the locus responsible for the isolated clinical anophthalmia phenotype in the selected family, genomic DNA from each individual was genotyped using a microsatellite short tandem repeat (STR) marker for the known clinical anophthalmia loci ([Table 1](#j_bjmg-2016-0010_tab_001){ref-type="table"}). The microsatellite markers for each locus were amplified by polymerase chain reaction (PCR). Each PCR reaction was performed in a 10 μL volume, containing 1.5 mM MgCl~2~, 0.6 μM of each forward and reverse primer, 0.2 mM dNTPs, 1 U Taq DNA polymerase and PCR buffer \[16 mM (NH~4~) ~2~SO~4~, 67 mM Tris-HCl (pH 8.8), and 0.01% of the nonionic detergent Tween-20\] (Bioline Reagents Ltd., London, UK). Amplification was performed with an initial denaturation for 4 min. at 94 °C, followed by 35 cycles of denaturation at 94 °C for 35 seconds, annealing at 55 °C for 35 seconds, extension at 72 °C for 35 seconds, and a final extension at 72 °C for 7 min. The PCR products were separated on 10.0% nondenaturing polyacrylamide gels (Protogel; National Diagnostics, Edinburgh, Scotland, UK). The gel was stained with ethidium bromide and photographed under UV illumination. Alleles were assigned to individuals and genotypic data was used to find genotypes of all individuals of this family. The phenotype was analyzed as an autosomal recessive trait.

###### 

List of short tandem repeat markers used for genotyping in clinical anophthalmia.

  ----------------------------------------------------------------------------
  Chromosome   Gene      STR Markers   Distance (cM)   Amplified Length (bp)
  ------------ --------- ------------- --------------- -----------------------
  14q32        --        D14S617\      91.0\           141-173\
                         GATA168F06\   92.6\           212-232\
                         GATA136B01    97.0            133-157

  14q24.3      *CHX10*   D14S588\      71.0\           117-141\
                         D14S53\       82.7\           151-155\
                         D14S606       85.9            254-286

  18q21.3      *RAX*     D18S858\      54.9\           193-208\
                         ATA7D07\      64.7\           126-147\
                         D18S64        60.1            188-208

  14q21-22     *OTX2*    GATA168F06\   92.6\           212-232\
                         GATA136B01    97.0            133-157

  3q26.3-q27   *SOX2*    D3S1565\      190.3\          239-245\
                         D3S2427\      192.1\          203-245\
                         D3S1262\      205.2\          100-132\
                         D3S2436\      208.5\          164-180\
                         D3S1580\      208.7\          139-155\
                         D3S1311       213.1           128-160
  ----------------------------------------------------------------------------

cM: centimorgan; bp: base pair.

Mutation Screening {#j_bjmg-2016-0010_s_002_s_004}
------------------

All individuals of this family were screened for mutations in the candidate gene. Polymerase chain reaction amplification of DNA of both normal and affected individuals was performed with forward and reverse primers sets, spanning the whole exonic region and promoter region of the candidate gene ([Tables 2](#j_bjmg-2016-0010_tab_002){ref-type="table"} and [3](#j_bjmg-2016-0010_tab_003){ref-type="table"}) that were designed using online available Primer 3 (<http://primer3plus.comweb_3.0.0/primer3web_input.htm>) software. The PCR amplification was performed in a 50 μL reaction volume containing 250 ng of genomic DNA, amplification buffer containing 600 nM of each primer, 1.5 mM MgCl2, 200 mM of dNTPs and 2.5 U of Taq DNA polymerase (Applied Biosystems Ltd., Warrington, Cheshire, UK) in an PxE thermal cycler (Hybaid, Basingstoke, Hampshire, UK). The amplification conditions were 95 °C for 5 min., followed by 35 cycles of 95 °C for 45 seconds, primer specific annealing temperature (55 to 65 °C) for 45 seconds, and 72 °C for 45 seconds. Aliquots (5 \#x03BC;L) of the PCR products were analyzed by 2 to 2.5% agarose gel. The PCR products were then purified using QIAquick PCR Purification Kit (Qiagen Ltd., Crawley, West Sussex, UK) and sequenced directly using Big Dye® Terminator v3.1 cycle sequencing kit in an ABI PRISM® 3130 genetic analyzer (Applied Biosystems, Foster City, CA, USA).

###### 

Primer sets used for amplification of the single exon of the *SOX2* gene.

  ------------------------------------------------------------------
  Primers     Sequences (5'\>3')            PCR Fragment Size (bp)
  ----------- ----------------------------- ------------------------
  Sox2_1aF\   CCT CTC TCT TTT TTT CCC C\    431
  Sox2_1aR    TCT CCG ACA AAA GTT TCC       

  Sox2_1bF\   GCG GCA ACC AGA AAA ACA\      291
  Sox2_1bR    GCA GCG TGT ACT TAT CCT T     

  Sox2 1cF\   GCT CAT GAA GAA GGA TAA GT\   283
  Sox2_1cR    GCT GGT CAT GGA GTT GTA       

  Sox2 1dF\   CAT GAA CGG CTG GAG CAA\      407
  Sox2_1dR    AGT GCT GGG ACA TGT GAA       

  Sox2_1eF\   TTA CCT CTT CCT CCC ACT C\    286
  Sox2_1eR    CTC CAT GCT GTT TCT TAC T     
  ------------------------------------------------------------------

PCR: polymerase chain reaction; bp: base pair; F: forward; R: reverse.

###### 

Primer sets used for amplification of the promoter sequence of the *SOX2* gene.

  ---------------------------------------------------------------------
  Primers     Sequences (5'\>3')               PCR Fragment Size (bp)
  ----------- -------------------------------- ------------------------
  5' F2\      AGT CCC GGC CGG GCC GAG\         602
  5' R3       GGT AGC CCA GCT GGT CCT G        

  3' F\       GGC GTG AAC CAG CGC ATG G\       612
  3' R        GGA GCG TAC CGG GTT TTC TC       

  5'UTR F\    CGC TGA TTG GTC GCT AGA A\       518
  5'UTR R     CTT CAG CTC CGT CTC CAT CAT      

  3'UTR.1F\   GGG GTG CAA AAG AGG AGA GTA\     490
  3'UTR.1R    GAA AAA TAT TGG CAA ATT CTC GC   

  3'UTR.2F\   AAC ATG GCA ATC AAA ATG TCC\     514
  3'UTR.2R    ATT CTC GGC AGA CTG ATT CAA      

  3'UTR.3F\   CCC CCT TTA TTT TCC GTA GTT\     353
  3'UTR.3R    ATC ATC CAG CCG TTT CTT TTT      
  ---------------------------------------------------------------------

PCR: polymerase chain reaction; bp: base pair; F: forward; R: reverse; 5'UTR: 5' untranslated region; 3'UTR: 3' untrans-lated region.

Results {#j_bjmg-2016-0010_s_005}
=======

In an ascertained consanguineous family with isolated clinical anophthalmia, the phenotypically normal parents with pedigree ID 2MOP001and 2MOP002, produced two affected daughters with pedigree ID 2MOP003 and 2MOP 006 ([Figure 3](#j_bjmg-2016-0010_fig_003){ref-type="fig"}). The proband, (2MOP003), was the first daughter identified with bilateral clinical anophthalmia, and she helped in tracing the disease in this family. Bilateral clinical anophthalmia was present at birth in both the affected daughters and the ages of these affected daughters were between 4-13 years.

![Pedigree of a consanguineous Pakistani family with STR genotyping data mapped to a locus on chromosome 3q26.3-q27. Both parents are carriers of the defective (boxed) chromosome. The affected individuals (filled square and circles) are homozygotes for the defective chromosome.](j_bjmg-2016-0010_fig_003){#j_bjmg-2016-0010_fig_003}

In this study, no evidence of linkage was observed with any of the STR markers for the 14q32, 14q24.3, 18q 21.3 and 14q21-22 loci and were therefore excluded. However, in view of the obtained results, this family with clinical anophthalmia was mapped to a locus on chromosome 3q26.3-q27, where the *SOX2* gene resides, as affected daughters showed homozygosity for this locus within a 3 cM (centimorgan) in this region for STR markers D3S 2427, D3S1262, D1S2436 and D3S1580 ([Figure 4](#j_bjmg-2016-0010_fig_004){ref-type="fig"}). In the pedigree under study, the parents of the affected daughters were first cousins, and both carried the same disease chromosome in a heterozygous state ([Figure 3](#j_bjmg-2016-0010_fig_003){ref-type="fig"}). However, the mutations were not identified in the single exonic sequence and regulatory element of the *SOX2* gene by comprehensive mutational analysis of both normal and affected individuals. Only two individuals were found to be affected, thus, the Lod score genes could not be calculated to examine the combined effects of the genes.

![Gel electropherograms for STR markers D3S1262, D3S2436 and D3S1580, demonstrating homozygosity for the affected members (2MOP003 and 2MOP006) in the studied family.](j_bjmg-2016-0010_fig_004){#j_bjmg-2016-0010_fig_004}

Discussion {#j_bjmg-2016-0010_s_006}
==========

The term clinical anophthalmia was first used by Duke-Elder \[[@j_bjmg-2016-0010_ref_008]\], and is a rare disease. The reported average prevalence of congenital anophthalmia is three in 100,000 \[[@j_bjmg-2016-0010_ref_014]\]. Clinical anophthalmia is the absence of the eye and diagnosed without histological examination \[[@j_bjmg-2016-0010_ref_022]\]. The most common phenotype in affected individuals is bilateral anophthalmia \[[@j_bjmg-2016-0010_ref_004]\], and unilateral anophthalmia may rarely be seen \[[@j_bjmg-2016-0010_ref_005]\].

In the present study, we reported a consanguineous family with two affected daughters of isolated clinical anophthalmia from the Kohat region of Khyber Pakhtunkhwa, Pakistan. Affected daughters do not have any congenital malformations except for bilateral clinical anophthalmia. In addition, the family history showed that there was no other member with anophthalmia. In the pedigree under study, the affected daughters have unaffected parents, who are first cousins, thus inheritance is undoubtedly autosomal recessive. Moreover, members of this family practiced consanguineous marriages to follow the family tradition of marriages between cousins. Consanguinity in a family as a risk factor and consequently autosomal recessive mode of inheritance for clinical anophhalmia, has rarely been reported \[[@j_bjmg-2016-0010_ref_001],[@j_bjmg-2016-0010_ref_008],[@j_bjmg-2016-0010_ref_010],[@j_bjmg-2016-0010_ref_011]\]. However, X-linked inher-itance has been described for clinical anophthalmia \[[@j_bjmg-2016-0010_ref_004],[@j_bjmg-2016-0010_ref_023]\]. Epidemiological studies have also reported other risk factors including late maternal age, multiple births, low birth weight, premature birth complications, mechanical abortion and severe vitamin A deficiency \[[@j_bjmg-2016-0010_ref_004],[@j_bjmg-2016-0010_ref_015],[@j_bjmg-2016-0010_ref_016],[@j_bjmg-2016-0010_ref_018]\]. These risk factors were not identified in this family as a cause of clinical anophthalmia.

In the present study, linkage analysis of family was performed with STR markers corresponding to the candidate genes involved in clinical anophthalmia phenotypes. This Pakistani family was linked to a locus at chromosome 3q26.3-q27, which carries the *SOX2* gene. The critical disease region was flanked by STR markers D3S1565 and D3S1311 in the affected daughters; therefore, it is probable that the disease gene lies between these two markers within a region of approximately 23 cM on chromosome 3. However, the affected daughters showed homozygosity in the disease region of approximately 3 cM for markers D3S 1262, D1S2436 and D3S1580. The linkage data presented in this study suggested that a gene for clinical anophthalmia was present within the region of homozygosity at chromosome 3. However, mutation screening did not reveal any mutation in the exonic sequence and regulatory element of the *SOX2* gene in the parents and offspring of this family. This indicates that another gene might possibly be present in the mapped region for disease phenotype and needs to be identified and screened to identify the disease-associated mutation in this family. The Lod score calculation in linkage analysis is very successful in mapping Mendelian disease genes or to examine combined effects of genes. However, the Lod score could not be calculated, as there were only two affected daughters, and that is the limitation of our study.

The severity of clinical anophthalmia is variable due to mutations in various human genes that are associated with anophthalmia \[[@j_bjmg-2016-0010_ref_004],[@j_bjmg-2016-0010_ref_005]\]. Among these, the *SOX2* has been reported as a major causative gene for clinical anophthalmia \[[@j_bjmg-2016-0010_ref_004]\]. By genetic analysis, the single-exon *SOX2* gene was identified in an intron of a noncoding *SOX2OT* (SOX2 overlapping transcript) gene \[[@j_bjmg-2016-0010_ref_024]\]. By using the fluorescent *in situ* hybridization (FISH) approach, the *SOX2* gene was mapped to chromosome 3q26.3-q27 \[[@j_bjmg-2016-0010_ref_025]\]. The *SOX2* gene is universally expressed in neural stem and neural precursor cells throughout the central nervous system including the neural retina \[[@j_bjmg-2016-0010_ref_026]-[@j_bjmg-2016-0010_ref_028]\], and mutations in this gene are common causes of retinal and ocular malformations in humans.

By sequence analysis of the coding region of the *SOX2* gene, a heterozygous loss-of-function mutation was identified in individuals with unilateral and bilateral anophthalmia in various research studies. By SOX2 mutation analysis in four unrelated individuals with unilateral or bilateral clinical anophthalmia, Fantes *et al*. \[[@j_bjmg-2016-0010_ref_024]\] identified heterozygous *de novo* truncating mutations in the *SOX2* gene. Similarly, in an 11-month-old Mexican female infant with bilateral clinical anophthalmia and brain malformations, Zenteno *et al*. \[[@j_bjmg-2016-0010_ref_029]\] identified heterozygosity for a 20 bp deletion in the *SOX2* gene. *De novo* missense mutations and frameshift mutations in the heterozygous state in the coding region of the *SOX2* gene in patients with bilateral anophthalmia/ microphthalmia were also reported \[[@j_bjmg-2016-0010_ref_030]\].

In a 12-year-old girl with congenital bilateral clinical anophthalmia, a heterozygous nonsense mutation in the *SOX2* gene was found \[[@j_bjmg-2016-0010_ref_031]\]. Similarly, a heterozygous missense mutation was found in the *SOX2* gene in a girl with bilateral clinical anophthalmia. However, the clinically normal mother was found to be heterozygous for this mutation \[[@j_bjmg-2016-0010_ref_032]\]. The *SOX2* gene was analyzed in two female siblings with clinical bilateral anophthalmia and found heterozygosity for a 17 bp deletion on this gene \[[@j_bjmg-2016-0010_ref_006],[@j_bjmg-2016-0010_ref_033]\]. Similarly, in an Italian male with clinical bilateral anophthalmia and micropenis, a heterozygous insertion mutation was reported in the *SOX2* gene responsible for such phenotypes \[[@j_bjmg-2016-0010_ref_034]\].

Conclusions {#j_bjmg-2016-0010_s_007}
===========

In conclusion, the phenotypically normal parents of the affected daughters were first cousins, and both carried disease chromosome in the heterozygous state, and their affected daughters were homozygotes. Therefore, the present study strongly supports the fact on the basis of pedigree and linkage analysis that the consanguineous marriage contributed to the congenital isolated clinical anophthalmia that is inherited in an autosomal recessive manner. Moreover, this study could not reveal a molecular basis for congenital clinical anophthalmia in this family, as a consequence of mutations in the *SOX2* gene. If more samples of congenital clinical anophthalmia subjects would be investigated in families of the same ethnic group, a better estimation of disease-related genes other than *SOX2*, but not yet identified in congenital isolated clinical anophthalmia, could be made in future.
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